Cendakimab Biosimilar (IL-13 Reference Antibody)
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .
Product Specifications
Target
Cendakimab Biosimilar (Anti-IL-13 Reference Antibody)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Purity
>98%
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
ZW10 (Centromere/kinetochore Protein zw10 Homolog, zw10 Kinetochore Protein, HZW10, KNTC1AP) (AP)
ZW10 (Centromere/kinetochore Protein zw10 Homolog, zw10 Kinetochore Protein, HZW10, KNTC1AP) (AP)
